Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
144 hedge funds and large institutions have $345M invested in Catalyst Pharmaceutical in 2021 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 43 increasing their positions, 53 reducing their positions, and 15 closing their positions.
47% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 15
4% more funds holding
Funds holding: 139 → 144 (+5)
0.08% less ownership
Funds ownership: 63.36% → 63.28% (-0.08%)
8% less capital invested
Capital invested by funds: $376M → $345M (-$31.1M)
19% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 53
56% less call options, than puts
Call options by funds: $491K | Put options by funds: $1.11M
Top Buyers
| 1 |
LSV Asset Management
Chicago,
Illinois
|
+$5.57M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.91M |
| 3 |
Aviva
London,
United Kingdom
|
+$1.78M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.6M |
| 5 |
CIC
Cornercap Investment Counsel
Atlanta,
Georgia
|
+$1.18M |
Top Sellers
| 1 |
Goldman Sachs
New York
|
-$1.93M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.89M |
| 3 |
GC
Globeflex Capital
San Diego,
California
|
-$1.68M |
| 4 |
Two Sigma Advisers
New York
|
-$1.55M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$1.5M |
CPRX Hedge Fund Activity: Q3 2021 in Review
144 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q3 2021, worth a combined $345M — down 8.3% from $376M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new CPRX positions and 15 closed out — a net gain of 7 holders — while 43 added to existing stakes and 53 trimmed.
The largest buyer was LSV Asset Management, adding an estimated $5.57M. The largest seller was Goldman Sachs, cutting an estimated $1.93M.
- 144 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q3 2021, up from 139 in Q2 2021.
- Funds reported $345M of Catalyst Pharmaceutical stock for Q3 2021, down 8.3% quarter-over-quarter.
- 22 funds opened new Catalyst Pharmaceutical positions in Q3 2021 and 15 closed out, a net change of +7 holders.
- The largest Catalyst Pharmaceutical buyer in Q3 2021 was LSV Asset Management, an estimated $5.57M added.
- The largest Catalyst Pharmaceutical seller in Q3 2021 was Goldman Sachs, an estimated $1.93M sold.
Based on aggregated 13F filings for Q3 2021.